Category: Regulatory DisclosuresBy adminJanuary 5, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda acquires exclusive rights for the distribution and marketing of “Physiomer” in EgyptNextNext post:Disclosure to the EGX on the Organizational StructureRelated PostsRameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024
